ATE433115T1 - Timp-2 als ziel/marker des versagens von beta- zellen - Google Patents

Timp-2 als ziel/marker des versagens von beta- zellen

Info

Publication number
ATE433115T1
ATE433115T1 AT05760716T AT05760716T ATE433115T1 AT E433115 T1 ATE433115 T1 AT E433115T1 AT 05760716 T AT05760716 T AT 05760716T AT 05760716 T AT05760716 T AT 05760716T AT E433115 T1 ATE433115 T1 AT E433115T1
Authority
AT
Austria
Prior art keywords
timp
marker
target
cell failure
beta cell
Prior art date
Application number
AT05760716T
Other languages
English (en)
Inventor
Andreas Christ
Stefan Evers
Kurt Krapfenbauer
Elena Sebokova
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE433115T1 publication Critical patent/ATE433115T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT05760716T 2004-07-28 2005-07-19 Timp-2 als ziel/marker des versagens von beta- zellen ATE433115T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04103608 2004-07-28
PCT/EP2005/007853 WO2006010529A1 (en) 2004-07-28 2005-07-19 Timp-2 as target/marker of beta cell failure

Publications (1)

Publication Number Publication Date
ATE433115T1 true ATE433115T1 (de) 2009-06-15

Family

ID=34972635

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05760716T ATE433115T1 (de) 2004-07-28 2005-07-19 Timp-2 als ziel/marker des versagens von beta- zellen

Country Status (9)

Country Link
US (1) US20100009462A1 (de)
EP (1) EP1774338B1 (de)
JP (1) JP4562771B2 (de)
CN (1) CN1993619A (de)
AT (1) ATE433115T1 (de)
CA (1) CA2574417C (de)
DE (1) DE602005014778D1 (de)
ES (1) ES2325789T3 (de)
WO (1) WO2006010529A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011075744A1 (en) 2009-12-20 2011-06-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2734494T3 (es) 2011-12-08 2019-12-10 Astute Medical Inc Métodos y usos para el diagnóstico de una lesión renal y de una insuficiencia renal
PL2946211T3 (pl) 2013-01-17 2018-08-31 Astute Medical, Inc. Sposoby i kompozycje do diagnozowania i prognozowania uszkodzenia oraz niewydolności nerek
CA2920521A1 (en) * 2013-08-07 2015-02-12 Astute Medical, Inc. Assays for timp2 having improved performance in biological samples
EP3077819A4 (de) 2013-12-03 2017-06-28 Astute Medical, Inc. Verfahren und zusammensetzungen zur diagnose und prognose von nierenläsion und niereninsuffizienz
WO2016164854A1 (en) 2015-04-09 2016-10-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2017277305A1 (en) 2016-06-06 2018-12-20 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
US10224053B2 (en) * 2017-03-24 2019-03-05 Hyundai Motor Company Audio signal quality enhancement based on quantitative SNR analysis and adaptive Wiener filtering
EP3606554A4 (de) * 2017-04-05 2020-12-09 Astute Medical, Inc. Tests auf timp2 mit verbesserter leistung bei biologischen proben

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1181939B1 (de) * 1999-05-24 2006-05-31 Shionogi & Co., Ltd. Methode zum auswerten der in vivo matrix-metalloproteinasen hemmenden aktivität
US6673623B1 (en) * 2000-09-12 2004-01-06 Novocure, Inc. Methods and compositions that control lipid production
AUPS282002A0 (en) * 2002-06-06 2002-06-27 Gropep Limited Metalloproteinase inhibitors

Also Published As

Publication number Publication date
JP2008508502A (ja) 2008-03-21
EP1774338B1 (de) 2009-06-03
CN1993619A (zh) 2007-07-04
CA2574417A1 (en) 2006-02-02
CA2574417C (en) 2010-09-28
EP1774338A1 (de) 2007-04-18
WO2006010529A1 (en) 2006-02-02
ES2325789T3 (es) 2009-09-17
JP4562771B2 (ja) 2010-10-13
DE602005014778D1 (de) 2009-07-16
US20100009462A1 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
ATE433115T1 (de) Timp-2 als ziel/marker des versagens von beta- zellen
WO2008030273A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2006084195A3 (en) Personal assessment including familial risk analysis for personalized disease prevention plan
EA200971079A1 (ru) ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ В Chr5p12 И 10q26 В КАЧЕСТВЕ МАРКЕРОВ ДЛЯ ПРИМЕНЕНИЯ ПРИ ОЦЕНКЕ РИСКА, ДИАГНОСТИРОВАНИИ, ПРОГНОЗИРОВАНИИ И ЛЕЧЕНИИ РАКА ГРУДИ
ES2572372T3 (es) Método de diagnóstico de enfermedades neurodegenerativas basado en la medición de los niveles o de la actividad de SIRT1
ATE476657T1 (de) Vorhersage von letalität und detektion von schweren erkrankungen
EP2546649A3 (de) Biomarker für Fettleberkrankheit und Verfahren zur Verwendung davon
WO2006133287A3 (en) Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases
DE602006011896D1 (de) Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden
ATE535612T1 (de) Toxizitätsscreeningverfahren
WO2006084101A3 (en) Method and apparatus for determining familial risk of disease
DE602006016589D1 (de) Neue markierungsstrategien für den empfindlichen nachweis von analyten
WO2008122670A3 (en) Human diabetes susceptibility tnfrsf10b gene
ATE484505T1 (de) 5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin- - olderivate als cxcr2-antagonisten
ATE537445T1 (de) Screening-verfahren
WO2007059064A3 (en) Fgf2-related methods for diagnosing and treating depression
WO2007134028A3 (en) Biomarkers for depression and methods using the same
WO2006010533A3 (en) Pancreatic polypeptide as target/marker of beta cell failure
WO2008060400A3 (en) Sirtuin polymorphisms and methods of use thereof
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome
DE602005010712D1 (de) Insulinpromotor-faktor 1 als target/marker von beta-zellen-störung
FR2930036B1 (fr) Procede de diagnostic d'une hypertension arterielle pulmonaire.
WO2009029587A3 (en) Compositions and methods for diagnosing and treating macular degeneration
ITRM20050398A1 (it) Metodo per la rilevazione di cellule t in pazienti neodiagnosticati per diabete di tipo 1.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties